论文部分内容阅读
在晚期何杰金氏病的解救治疗中,ABVD及一些含有环己亚硝脲的方案可获得30％～60％的CR率,但仅20％～30％的病人可达5年无瘤生存,ABVD或MOPP/ABVD方案交替治疗在CR率及无瘤生存方面优于单一应用MOPP方案,而前二者之间无差别。EVA(VP-16,VCR,ADM)方案是ABVD的改进方案。无肺毒性,VP-16的剂量还可进一步提高,其二线治疗效果与ABVD方案相同。大剂量化、放疗联合自体骨髓移植适用于在应用上述二种不同化疗方案后仍无效的病人,其CR率为46％,35％的病人可达3年无瘤生存。
In the late rescue treatment of Hodgkin’s disease, ABVD and some regimens containing cyclohexyl nitrosourea can obtain a CR rate of 30% to 60%, but only 20% to 30% of patients can achieve 5 years of tumor-free survival. Alternating treatment with ABVD or MOPP/ABVD regimen was superior to single-use MOPP regimen in CR rate and disease-free survival, with no difference between the first two groups. The EVA (VP-16, VCR, ADM) solution is an improvement of ABVD. Without pulmonary toxicity, the dose of VP-16 can be further increased, and its second-line treatment effect is the same as that of the ABVD protocol. High-dose, radiotherapy combined with autologous bone marrow transplantation is suitable for patients who are still ineffective after applying the above two different chemotherapy regimens. The CR rate is 46%, and 35% of patients can survive for 3 years without tumor.